Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

 SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtypes of Epidermolysis Bullosa MOUNT PLEASANT, S.C., Oct. 22, 2026 /PRNewswire/ -- Paradigm Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare diseases, today announced that the first patient has been enrolled in its Phase 3 clinical trial (SD-007) evaluating SD-101 (Zorblesia™), an investigational topical cream for the treatment of chronic wounds and skin lesions asso…READ FULL ARTICLE